Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results